Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Paolo G. Casali, Vittorio Quagliuolo et al.|The Lancet Oncology|2017

Cited by 493